Working with some of the world’s largest pharmaceutical and consumer product companies, we have a track record of collaborating from initial product concept through commercial GMP manufacture by leveraging our technologies, formulation and development expertise.
We welcome the opportunity to solve complex transdermal challenges that create new markets with first-in-patch products.
Corium is currently seeking strategic partnerships in the following areas:
- Commercial marketing rights outside the United States for our CorplexTM Donepezil and Corplex Memantine product candidates for the treatment of Alzheimer’s disease;
- The development and commercialization of our MicroCor® PTH(1-34), a first-in-class biodegradable microstructure formulation of parathyroid hormone for the treatment of osteoporosis; and
- The evaluation, development, and commercialization of new products combining our Corplex and/or MicroCor delivery systems with our partner’s proprietary molecules.
In addition, we look forward to speaking with potential partners regarding manufacturing opportunities for other transdermal products.
Please for more information.